Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 315

1.

Biomarkers of Infection and Sepsis.

Opal SM, Wittebole X.

Crit Care Clin. 2020 Jan;36(1):11-22. doi: 10.1016/j.ccc.2019.08.002. Epub 2019 Oct 21. Review.

PMID:
31733673
2.

Should we continue to test soluble thrombomodulin, or other systemic anticoagulants, as a life-saving therapy for sepsis-induced coagulopathy?

Laterre PF, Levy MM, Wittebole X, Dugernier T, Francois B, Opal SM.

Anaesth Crit Care Pain Med. 2019 Oct;38(5):419-421. doi: 10.1016/j.accpm.2019.09.003. No abstract available.

PMID:
31585759
3.

Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical Trial.

Laterre PF, Berry SM, Blemings A, Carlsen JE, François B, Graves T, Jacobsen K, Lewis RJ, Opal SM, Perner A, Pickkers P, Russell JA, Windeløv NA, Yealy DM, Asfar P, Bestle MH, Muller G, Bruel C, Brulé N, Decruyenaere J, Dive AM, Dugernier T, Krell K, Lefrant JY, Megarbane B, Mercier E, Mira JP, Quenot JP, Rasmussen BS, Thorsen-Meyer HC, Vander Laenen M, Vang ML, Vignon P, Vinatier I, Wichmann S, Wittebole X, Kjølbye AL, Angus DC; SEPSIS-ACT Investigators.

JAMA. 2019 Oct 2. doi: 10.1001/jama.2019.14607. [Epub ahead of print] Erratum in: JAMA. 2019 Oct 15;:.

PMID:
31577035
4.

An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic.

Opal S, File TM, van der Poll T, Tzanis E, Chitra S, McGovern PC.

Clin Infect Dis. 2019 Aug 1;69(Supplement_1):S40-S47. doi: 10.1093/cid/ciz398.

5.

Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis.

Seymour CW, Kennedy JN, Wang S, Chang CH, Elliott CF, Xu Z, Berry S, Clermont G, Cooper G, Gomez H, Huang DT, Kellum JA, Mi Q, Opal SM, Talisa V, van der Poll T, Visweswaran S, Vodovotz Y, Weiss JC, Yealy DM, Yende S, Angus DC.

JAMA. 2019 May 28;321(20):2003-2017. doi: 10.1001/jama.2019.5791.

6.

Effect of a Recombinant Human Soluble Thrombomodulin on Mortality in Patients With Sepsis-Associated Coagulopathy: The SCARLET Randomized Clinical Trial.

Vincent JL, Francois B, Zabolotskikh I, Daga MK, Lascarrou JB, Kirov MY, Pettilä V, Wittebole X, Meziani F, Mercier E, Lobo SM, Barie PS, Crowther M, Esmon CT, Fareed J, Gando S, Gorelick KJ, Levi M, Mira JP, Opal SM, Parrillo J, Russell JA, Saito H, Tsuruta K, Sakai T, Fineberg D; SCARLET Trial Group.

JAMA. 2019 May 28;321(20):1993-2002. doi: 10.1001/jama.2019.5358.

7.

Inter-α-inhibitor Ameliorates Endothelial Inflammation in Sepsis.

Stober VP, Lim YP, Opal S, Zhuo L, Kimata K, Garantziotis S.

Lung. 2019 Jun;197(3):361-369. doi: 10.1007/s00408-019-00228-1. Epub 2019 Apr 26.

PMID:
31028466
8.

Physician agreement on the diagnosis of sepsis in the intensive care unit: estimation of concordance and analysis of underlying factors in a multicenter cohort.

Lopansri BK, Miller Iii RR, Burke JP, Levy M, Opal S, Rothman RE, D'Alessio FR, Sidhaye VK, Balk R, Greenberg JA, Yoder M, Patel GP, Gilbert E, Afshar M, Parada JP, Martin GS, Esper AM, Kempker JA, Narasimhan M, Tsegaye A, Hahn S, Mayo P, McHugh L, Rapisarda A, Sampson D, Brandon RA, Seldon TA, Yager TD, Brandon RB.

J Intensive Care. 2019 Feb 21;7:13. doi: 10.1186/s40560-019-0368-2. eCollection 2019.

9.

Novel Chitohexaose Analog Protects Young and Aged mice from CLP Induced Polymicrobial Sepsis.

Das P, Panda SK, Agarwal B, Behera S, Ali SM, Pulse ME, Solomkin JS, Opal SM, Bhandari V, Acharya S.

Sci Rep. 2019 Feb 27;9(1):2904. doi: 10.1038/s41598-019-38731-3.

10.

Coinfection With Influenza A Virus and Klebsiella oxytoca: An Underrecognized Impact on Host Resistance and Tolerance to Pulmonary Infections.

Lee KM, Morris-Love J, Cabral DJ, Belenky P, Opal SM, Jamieson AM.

Front Immunol. 2018 Oct 29;9:2377. doi: 10.3389/fimmu.2018.02377. eCollection 2018.

11.

Whatever happened to the Shwartzman phenomenon?

Chahin AB, Opal JM, Opal SM.

Innate Immun. 2018 Nov;24(8):466-479. doi: 10.1177/1753425918808008. Review.

12.

Antibiotic Stewardship: Strategies to Minimize Antibiotic Resistance While Maximizing Antibiotic Effectiveness.

Cunha CB, Opal SM.

Med Clin North Am. 2018 Sep;102(5):831-843. doi: 10.1016/j.mcna.2018.04.006. Review.

PMID:
30126574
13.

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis.

Banerjee D, Monaghan S, Zhao R, Walsh T, Palmisciano A, Phillips GS, Opal S, Levy MM.

Crit Care. 2018 Jun 7;22(1):146. doi: 10.1186/s13054-018-2064-3. No abstract available.

14.

Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study).

Welte T, Dellinger RP, Ebelt H, Ferrer M, Opal SM, Singer M, Vincent JL, Werdan K, Martin-Loeches I, Almirall J, Artigas A, Ignacio Ayestarán J, Nuding S, Ferrer R, Sirgo Rodríguez G, Shankar-Hari M, Álvarez-Lerma F, Riessen R, Sirvent JM, Kluge S, Zacharowski K, Bonastre Mora J, Lapp H, Wöbker G, Achtzehn U, Brealey D, Kempa A, Sánchez García M, Brederlau J, Kochanek M, Reschreiter HP, Wise MP, Belohradsky BH, Bobenhausen I, Dälken B, Dubovy P, Langohr P, Mayer M, Schüttrumpf J, Wartenberg-Demand A, Wippermann U, Wolf D, Torres A.

Intensive Care Med. 2018 Apr;44(4):438-448. doi: 10.1007/s00134-018-5143-7. Epub 2018 Apr 9.

15.

Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICU.

Miller RR 3rd, Lopansri BK, Burke JP, Levy M, Opal S, Rothman RE, D'Alessio FR, Sidhaye VK, Aggarwal NR, Balk R, Greenberg JA, Yoder M, Patel G, Gilbert E, Afshar M, Parada JP, Martin GS, Esper AM, Kempker JA, Narasimhan M, Tsegaye A, Hahn S, Mayo P, van der Poll T, Schultz MJ, Scicluna BP, Klein Klouwenberg P, Rapisarda A, Seldon TA, McHugh LC, Yager TD, Cermelli S, Sampson D, Rothwell V, Newman R, Bhide S, Fox BA, Kirk JT, Navalkar K, Davis RF, Brandon RA, Brandon RB.

Am J Respir Crit Care Med. 2018 Oct 1;198(7):903-913. doi: 10.1164/rccm.201712-2472OC.

16.

Towards precision medicine in sepsis: a position paper from the European Society of Clinical Microbiology and Infectious Diseases.

Rello J, van Engelen TSR, Alp E, Calandra T, Cattoir V, Kern WV, Netea MG, Nseir S, Opal SM, van de Veerdonk FL, Wilcox MH, Wiersinga WJ.

Clin Microbiol Infect. 2018 Dec;24(12):1264-1272. doi: 10.1016/j.cmi.2018.03.011. Epub 2018 Mar 24.

17.

Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shock-Adaptive Clinical Trial.

Lewis RJ, Angus DC, Laterre PF, Kjølbye AL, van der Meulen E, Blemings A, Graves T, Russell JA, Carlsen JE, Jacobsen K, Yealy DM, Opal SM, Windeløv NA, François B, Perner A, Pickkers P, Berry SM.

Ann Am Thorac Soc. 2018 Feb;15(2):250-257. doi: 10.1513/AnnalsATS.201708-669SD.

PMID:
29388815
18.

Age, exercise, and the outcome of sepsis.

Banerjee D, Opal SM.

Crit Care. 2017 Nov 23;21(1):286. doi: 10.1186/s13054-017-1840-9.

19.

Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration.

Meyer NJ, Reilly JP, Anderson BJ, Palakshappa JA, Jones TK, Dunn TG, Shashaty MGS, Feng R, Christie JD, Opal SM.

Crit Care Med. 2018 Jan;46(1):21-28. doi: 10.1097/CCM.0000000000002749.

20.

Visual pedagogy and probiotics for hearing impaired children: A pilot study.

Sujlana A, Goyal R, Pannu P, Opal S, Bansal P.

J Indian Soc Pedod Prev Dent. 2017 Oct-Dec;35(4):353-358. doi: 10.4103/JISPPD.JISPPD_146_17.

21.

The Role of S1PR3 in Protection from Bacterial Sepsis.

Shea BS, Opal SM.

Am J Respir Crit Care Med. 2017 Dec 15;196(12):1500-1502. doi: 10.1164/rccm.201708-1726ED. No abstract available.

PMID:
28910137
22.

Immunomodulatory oligonucleotide IMT504: Effects on mesenchymal stem cells as a first-in-class immunoprotective/immunoregenerative therapy.

Zorzopulos J, Opal SM, Hernando-Insúa A, Rodriguez JM, Elías F, Fló J, López RA, Chasseing NA, Lux-Lantos VA, Coronel MF, Franco R, Montaner AD, Horn DL.

World J Stem Cells. 2017 Mar 26;9(3):45-67. doi: 10.4252/wjsc.v9.i3.45. Review.

23.
24.

Should all septic patients be given systemic anticoagulation? No.

van der Poll T, Opal SM.

Intensive Care Med. 2017 Mar;43(3):455-457. doi: 10.1007/s00134-016-4607-x. Epub 2017 Feb 13. No abstract available.

PMID:
28194511
25.

Severe Pneumonia Caused by Legionella pneumophila: Differential Diagnosis and Therapeutic Considerations.

Chahin A, Opal SM.

Infect Dis Clin North Am. 2017 Mar;31(1):111-121. doi: 10.1016/j.idc.2016.10.009. Review.

PMID:
28159171
26.

Sepsis: frontiers in supportive care, organisation and research.

Perner A, Rhodes A, Venkatesh B, Angus DC, Martin-Loeches I, Preiser JC, Vincent JL, Marshall J, Reinhart K, Joannidis M, Opal SM.

Intensive Care Med. 2017 Apr;43(4):496-508. doi: 10.1007/s00134-017-4677-4. Epub 2017 Jan 27. Review.

PMID:
28130686
27.

Sepsis and septic shock.

Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL.

Nat Rev Dis Primers. 2016 Jun 30;2:16045. doi: 10.1038/nrdp.2016.45. Review.

28.

Evidence To Support Continuation of Statin Therapy in Patients with Staphylococcus aureus Bacteremia.

Caffrey AR, Timbrook TT, Noh E, Sakoulas G, Opal SM, Nizet V, LaPlante KL.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02228-16. doi: 10.1128/AAC.02228-16. Print 2017 Mar.

29.

Source Control in Sepsis Urgent or Not So Fast?

Opal SM.

Crit Care Med. 2017 Jan;45(1):130-132. No abstract available.

PMID:
27984280
30.

Non-antibiotic treatments for bacterial diseases in an era of progressive antibiotic resistance.

Opal SM.

Crit Care. 2016 Dec 16;20(1):397. doi: 10.1186/s13054-016-1549-1.

31.

The role of genetics and antibodies in sepsis.

Giamarellos-Bourboulis EJ, Opal SM.

Ann Transl Med. 2016 Sep;4(17):328. Review.

32.

A novel approach for emerging and antibiotic resistant infections: Innate defense regulators as an agnostic therapy.

North JR, Takenaka S, Rozek A, Kielczewska A, Opal S, Morici LA, Finlay BB, Schaber CJ, Straube R, Donini O.

J Biotechnol. 2016 May 20;226:24-34. doi: 10.1016/j.jbiotec.2016.03.032. Epub 2016 Mar 23.

33.

Long-Term Quality of Life Among Survivors of Severe Sepsis: Analyses of Two International Trials.

Yende S, Austin S, Rhodes A, Finfer S, Opal S, Thompson T, Bozza FA, LaRosa SP, Ranieri VM, Angus DC.

Crit Care Med. 2016 Aug;44(8):1461-7. doi: 10.1097/CCM.0000000000001658.

34.

Immunosuppression and Secondary Infection in Sepsis: Part, Not All, of the Story.

Angus DC, Opal S.

JAMA. 2016 Apr 12;315(14):1457-9. doi: 10.1001/jama.2016.2762. No abstract available.

PMID:
26975243
35.

PHARMACOLOGICAL SIRT1 ACTIVATION IMPROVES MORTALITY AND MARKEDLY ALTERS TRANSCRIPTIONAL PROFILES THAT ACCOMPANY EXPERIMENTAL SEPSIS.

Opal SM, Ellis JL, Suri V, Freudenberg JM, Vlasuk GP, Li Y, Chahin AB, Palardy JE, Parejo N, Yamamoto M, Chahin A, Kessimian N.

Shock. 2016 Apr;45(4):411-8. doi: 10.1097/SHK.0000000000000528.

PMID:
26974318
36.

Reply to "Generic Statins and Angiotensin Receptor Blockers: Are They Really Useful in Ebola?".

Fedson DS, Jacobson JR, Rordam OM, Opal SM.

mBio. 2016 Feb 23;7(1):e00094-16. doi: 10.1128/mBio.00094-16. No abstract available.

37.

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).

Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC.

JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.

38.

Isolating Influenza RNA from Clinical Samples Using Microfluidic Oil-Water Interfaces.

Cui FR, Wang J, Opal SM, Tripathi A.

PLoS One. 2016 Feb 17;11(2):e0149522. doi: 10.1371/journal.pone.0149522. eCollection 2016.

39.

THE EPITHELIUM AS A TARGET IN SEPSIS.

Chawla LS, Fink M, Goldstein SL, Opal S, Gómez A, Murray P, Gómez H, Kellum JA; ADQI XIV Workgroup.

Shock. 2016 Mar;45(3):249-58. doi: 10.1097/SHK.0000000000000518. Review.

PMID:
26863125
40.

Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.

Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, Cron RQ, Opal SM.

Crit Care Med. 2016 Feb;44(2):275-81. doi: 10.1097/CCM.0000000000001402.

41.

Is genomic medicine finally coming of age for the diagnosis of pneumonia?

Opal S.

Am J Respir Crit Care Med. 2015 Oct 1;192(7):773-4. doi: 10.1164/rccm.201507-1340ED. No abstract available.

PMID:
26426779
42.

The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance.

Walley KR, Francis GA, Opal SM, Stein EA, Russell JA, Boyd JH.

Am J Respir Crit Care Med. 2015 Dec 1;192(11):1275-86. doi: 10.1164/rccm.201505-0876CI.

PMID:
26252194
43.

NK and NKT Cell Depletion Alters the Outcome of Experimental Pneumococcal Pneumonia: Relationship with Regulation of Interferon-γ Production.

Christaki E, Diza E, Giamarellos-Bourboulis EJ, Papadopoulou N, Pistiki A, Droggiti DI, Georgitsi M, Machova A, Lambrelli D, Malisiovas N, Nikolaidis P, Opal SM.

J Immunol Res. 2015;2015:532717. doi: 10.1155/2015/532717. Epub 2015 May 31.

44.

Treating the Host Response to Ebola Virus Disease with Generic Statins and Angiotensin Receptor Blockers.

Fedson DS, Jacobson JR, Rordam OM, Opal SM.

mBio. 2015 Jun 23;6(3):e00716. doi: 10.1128/mBio.00716-15.

45.

Sepsis in the severely immunocompromised patient.

Kalil AC, Opal SM.

Curr Infect Dis Rep. 2015 Jun;17(6):487. doi: 10.1007/s11908-015-0487-4.

PMID:
25939918
46.

Sepsis: a roadmap for future research.

Cohen J, Vincent JL, Adhikari NK, Machado FR, Angus DC, Calandra T, Jaton K, Giulieri S, Delaloye J, Opal S, Tracey K, van der Poll T, Pelfrene E.

Lancet Infect Dis. 2015 May;15(5):581-614. doi: 10.1016/S1473-3099(15)70112-X. Epub 2015 Apr 19. Review. Erratum in: Lancet Infect Dis. 2015 Aug;15(8):875.

PMID:
25932591
47.

Concept for a study design in patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation - The CIGMA study.

Welte T, Dellinger RP, Ebelt H, Ferrer M, Opal SM, Schliephake DE, Wartenberg-Demand A, Werdan K, Löffler K, Torres A.

Respir Med. 2015 Jun;109(6):758-67. doi: 10.1016/j.rmed.2015.03.008. Epub 2015 Apr 2.

48.

Genetic factors affecting dental caries risk.

Opal S, Garg S, Jain J, Walia I.

Aust Dent J. 2015 Mar;60(1):2-11. doi: 10.1111/adj.12262. Review.

49.

The novel immunotherapeutic oligodeoxynucleotide IMT504 protects neutropenic animals from fatal Pseudomonas aeruginosa bacteremia and sepsis.

Chahin A, Opal SM, Zorzopulos J, Jobes DV, Migdady Y, Yamamoto M, Parejo N, Palardy JE, Horn DL.

Antimicrob Agents Chemother. 2015 Feb;59(2):1225-9. doi: 10.1128/AAC.03923-14. Epub 2014 Dec 15.

50.

Endothelial barrier dysfunction in septic shock.

Opal SM, van der Poll T.

J Intern Med. 2015 Mar;277(3):277-293. doi: 10.1111/joim.12331. Review.

Supplemental Content

Support Center